Netscientific Share Price (NSCI)

Sorry to be so ignorant but what has happened to this company. Is it still trading?

has been a pretty **** 5 year investment.

that much closer to some actual positive payouts/news but the market doesn't give a toss.

problem is investors have given up on aim and bent directors. (i'm not talking about nsci)

our lot need to send out a clear message with the results.

they are committed to our listing.

they won't do any more placings until we have a substantial improvement in the sp.

start the wheels turning to prepare for a buy back as funds come in.

across the board director buying post results.

buying our shares at 55p vs £2.00 is better than having to wait another 5/10 years for some new blue sky to come good.

make or break time for nsci/glycotest/qbot and a few others over the next 6 months.

hopefully it will be worth the wait.

EMV CAPITAL-BACKED GLYCOTEST™ PARTNERS WITH UNIVERSITY OF GEORGIA TO ACCELERATE NOVEL LIVER CANCER DIAGNOSTIC ASSAYS

SEPTEMBER 23, 2024-NEWS - NO COMMENTS - POSTED BY WEBMASTER

Merion, PA – 23 September 2024 – Glycotest, Inc. announces that it has entered into an agreement with the University of Georgia Complex Carbohydrate Research Center (CCRC) in Athens, GA to develop novel glycomic assays for its HCC Panel blood test, aimed at early-stage liver cancer detection. The agreement moves Glycotest towards commercializing its breakthrough platform, leveraging significant R&D efforts to tackle Hepatocellular Carcinoma (HCC), the most common and lethal form of liver cancer.

Under the terms of the agreement, Glycotest will fund the development of the new assays at the CCRC, with Glycotest securing exclusive rights to the resulting intellectual property. The new assays developed by the CCRC will be deployed by Glycotest in its HCC Panel test. The assay development work will be spearheaded by Dr. Parastoo Azadi, Associate Director of CCRC Service and Training.

Glycotest is a liver disease diagnostics company commercializing new and unique blood tests for liver cancers and fibrosis-cirrhosis. The Company has made huge strides in developing its innovative diagnostic technology and the deal with CCRC, a world leader in glycoscience, marks a crucial step toward market launch.

Charles Swindell, PhD, CEO, Glycotest, commented:

“Glycotest is fortunate to partner with the CCRC—a world renowned innovator in glycoscience testing methodology—on this final chapter in making the HCC Panel test available to liver disease patients and their physicians. We believe the HCC Panel could become a significant tool for better identification of early-stage HCC patients eligible for potentially curative therapy.”

The CCRC’s expertise will enhance Glycotest’s proprietary HCC Panel, which has already shown promise in identifying early-stage liver cancer—where treatment options can be most effective. The potential market is huge, with an estimated three million patients in the US, and potentially up to 380 million patients worldwide, eligible for routine HCC surveillance testing. Glycotest employs unique non-invasive blood tests based on proprietary serum glycoprotein biomarkers, biomarker panels and assay technology that exploit novel carbohydrate-based disease signal chemistry.

The CCRC is a long-standing center of excellence in the glycosciences, the branch of science that investigates the structure, biosynthesis, and biological functions of molecules that contain carbohydrates. With expertise and resources in a rich array of sophisticated instrumental techniques key to glycoscience research, the CCRC is uniquely positioned to collaborate with Glycotest on this important project focusing on the development of superior mass spectroscopy-based glycomic assays.

Parastoo Azadi, PhD, Associate Director of the CCRC-Service and T

New Website on the way!

13 September 2024

Hello and thanks for visiting! We’re currently in the process of updating our website to make it even better for you. We're enhancing our features, improving our content, and ensuring you have an even more seamless experience.

During this period, some parts of the site may be temporarily unavailable, and we appreciate your patience and understanding. If you need immediate assistance, please feel free to reach out to us through our contact page.

Stay tuned for our new look

There's been little share price excitement here since June - November 2021.